Skip to main content

IsoRay, Inc. (ISR)

NYSEAMERICAN: ISR · IEX Real-Time Price · USD
0.464 0.000 (-0.06%)
Dec 8, 2021 4:00 PM EST - Market closed
Market Cap65.83M
Revenue (ttm)10.23M
Net Income (ttm)-4.92M
Shares Out141.92M
EPS (ttm)-0.04
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume277,135
Open0.462
Previous Close0.464
Day's Range0.460 - 0.477
52-Week Range0.400 - 2.810
Beta0.99
AnalystsStrong Buy
Price Target1.63 (+251.4%)
Earnings DateNov 10, 2021

About ISR

Isoray, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. Isoray, Inc. was founded in 1998 and is ba...

IndustryBiotechnology
Founded1983
CEOLori Woods
Employees61
Stock ExchangeNYSEAMERICAN
Ticker SymbolISR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for IsoRay stock is "Strong Buy." The 12-month stock price forecast is 1.63, which is an increase of 251.37% from the latest price.

Price Target
$1.63
(251.37% upside)
Analyst Consensus: Strong Buy

News

Isoray Announces First Quarter Fiscal 2022 Financial Results

Prostate Revenue Increased Year-Over-Year for Second Consecutive Quarter Non-Prostate Brachytherapy Revenue Increased 20% Year-Over-Year

4 weeks ago - GlobeNewsWire

Will IsoRay (ISR) Report Negative Earnings Next Week? What You Should Know

IsoRay (ISR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Isoray To Announce First Quarter Fiscal 2022 Financial Results on November 10, 2021

Conference Call is Wednesday, November 10, 2021 at 4:30 p.m. ET/1:30 p.m. PT Conference Call is Wednesday, November 10, 2021 at 4:30 p.m. ET/1:30 p.m. PT

1 month ago - GlobeNewsWire

American Brachytherapy Society LDR Prostate Brachytherapy Treatment Consensus Paper Recognizes Isoray's Cesium-131

RICHLAND, Wash., Sept. 28, 2021 (GLOBE NEWSWIRE) -- The American Brachytherapy Society (ABS) has recognized Isoray's Cesium-131 in its recently released new consensus statement on the subject of low dos...

2 months ago - GlobeNewsWire

Recap: Isoray Q4 Earnings

Isoray(AMEX:ISR) stock fell by 3.68% on Wednesday after the company reported its Q4 earnings results on Tuesday, September 21, 2021 at 04:05 PM. Here's what investors need to know about the announcement.

2 months ago - Benzinga

Isoray Reschedules Fourth Quarter and Fiscal Year End 2021 Financial Results Conference Call to September 22, 2021 Du...

Conference Call Rescheduled for Wednesday, September 22 at 10:00 a.m. ET/7:00 a.m. PT Conference Call Rescheduled for Wednesday, September 22 at 10:00 a.m. ET/7:00 a.m. PT

2 months ago - GlobeNewsWire

IsoRay (ISR) Reports Q4 Loss, Tops Revenue Estimates

IsoRay (ISR) delivered earnings and revenue surprises of 0.00% and 3.99%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Isoray Announces Fourth Quarter and Full-Year Fiscal Year End 2021 Financial Results

Record Full Year Revenue Fiscal Fourth Quarter Revenue Increased 19% Year-Over-Year

2 months ago - GlobeNewsWire

Will IsoRay (ISR) Report Negative Q4 Earnings? What You Should Know

IsoRay (ISR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Isoray To Announce Fourth Quarter and Fiscal Year End 2021 Financial Results on September 21, 2021

Conference Call is Tuesday, September 21 at 4:30 p.m. ET/1:30 p.m. PT Conference Call is Tuesday, September 21 at 4:30 p.m. ET/1:30 p.m. PT

2 months ago - GlobeNewsWire

IsoRay (ISR) Reports Q3 Loss, Tops Revenue Estimates

IsoRay (ISR) delivered earnings and revenue surprises of 0.00% and 6.56%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Isoray Announces Third Quarter Fiscal 2021 Financial Results

Revenue Increased 10% Sequentially  Record Non-Prostate Brachytherapy Revenue Increased 20% Year-Over-Year

6 months ago - GlobeNewsWire

Isoray To Announce Third Quarter Fiscal 2021 Financial Results on May 13, 2021

Conference Call is Thursday, May 13 at 4:30 p.m. ET/1:30 p.m. PT Conference Call is Thursday, May 13 at 4:30 p.m. ET/1:30 p.m. PT

7 months ago - GlobeNewsWire

Isoray Announces the Appointment of Donna Fort as Vice President Sales and Marketing

RICHLAND, Wash., April 13, 2021 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE American: ISR), a medical technology company and seed brachytherapy innovator, today announced that Donna Fort has been appointed V...

7 months ago - GlobeNewsWire

University Hospitals Cleveland Medical Center Pilot Study Shows Promise for High-Risk Recurrent Head and Neck Cancer ...

RICHLAND, Wash., March 31, 2021 (GLOBE NEWSWIRE) -- A recently published small prospective series of patients with recurrent head and neck (H&N) cancers treated with surgical resection and Isoray's Cesi...

8 months ago - GlobeNewsWire

IsoRay (ISR) Reports Q2 Loss, Lags Revenue Estimates

IsoRay (ISR) delivered earnings and revenue surprises of 0.00% and -0.04%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

Isoray To Announce Second Quarter Fiscal 2021 Financial Results on February 9, 2021

Conference Call is Tuesday, February 9, 2021 at 4:30 p.m. ET/1:30 p.m. PT Conference Call is Tuesday, February 9, 2021 at 4:30 p.m. ET/1:30 p.m. PT

10 months ago - GlobeNewsWire

IsoRay (ISR) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

IsoRay (ISR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

10 months ago - Zacks Investment Research

7 Penny Stock Bubbles That Are About to Burst

There's an old saying that 'gaps refill'. And that means that these 7 penny stock Bubbles may be about to burst.

Other symbols:GHSIOBSVSBZOM
10 months ago - InvestorPlace

Isoray to Present at the H.C. Wainwright BioConnect 2021 Conference

RICHLAND, Wash., Jan. 07, 2021 (GLOBE NEWSWIRE) --  Isoray, Inc. (NYSE American: ISR), a medical technology company and seed brachytherapy innovator powering expanding treatment options throughout the b...

11 months ago - GlobeNewsWire

Why Change Healthcare, Isoray And Alkido Are Moving Today

Alkido Pharma (NASDAQ: AIKI) shares are trading higher after the company announced it executed a Patent License Agreement for technology that covers the use of psilocybin for cancer applications. AIkido...

Other symbols:CHNGAIKI
11 months ago - Benzinga

Isoray's Cesium-131 Spotlighted in Multiple Presentations at ASTRO

Studies Demonstrate Impact of Proprietary Isotope on Prostate and Brain Cancers At World's Premier Radiation Oncology Society Studies Demonstrate Impact of Proprietary Isotope on Prostate and Brain Canc...

1 year ago - GlobeNewsWire

IsoRay (ISR) Reports Q1 Loss, Lags Revenue Estimates

IsoRay (ISR) delivered earnings and revenue surprises of 0.00% and -21.32%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Isoray Announces First Quarter Fiscal 2021 Financial Results

Revenue Increased 3% Year-Over-Year

1 year ago - GlobeNewsWire

IsoRay (ISR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

IsoRay (ISR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research